...
首页> 外文期刊>Journal of vascular surgery >Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair
【24h】

Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair

机译:在腹主动脉瘤修复后,他汀类药物治疗与腹主动脉瘤后的长期但不围手术期生存有关

获取原文
获取原文并翻译 | 示例
           

摘要

BackgroundAlthough preoperative and perioperative statin therapy improves postoperative outcomes in several populations, few data examine its association with survival after abdominal aortic aneurysm (AAA) repair. In addition, no data exist regarding the benefits of starting statins in patients with AAA not currently taking them. MethodsWe performed a registry-based study of all patients undergoing repair of AAAs in the Vascular Quality Initiative between 2003 and 2017 without documented statin intolerance. In our primary analysis, we evaluated the association between preoperative statin therapy and long-term mortality, 30-day mortality, and in-hospital myocardial infarction and stroke. As a secondary analysis, we studied the cohort of patients not taking a statin preoperatively and compared their long-term mortality on the basis of whether they were discharged on a statin. To account for nonrandom assignment to treatment, we constructed propensity scores and applied inverse probability weighting. ResultsWe identified 40,452 AAA repairs, of which 37,950 fit our entry criteria (29,257 endovascular and 8693 open). Overall, 25,997 patients (69%) were taking a statin preoperatively, with patients undergoing endovascular aneurysm repair more frequently taking a statin than those undergoing open repair (69% compared with 66%;P?< .001). After propensity weighting, preoperative statin therapy was not associated with 30-day death or in-hospital stroke or myocardial infarction. However, patients taking statins preoperatively experienced higher adjusted 1-year (94% vs 90%) and 5-year (85% vs 81%) survival from the date of surgery compared with those who were not (P?< .001 overall), although subgroup analysis showed that this applied only to intact or symptomatic aneurysms. Of the 11,941 patients not taking a statin preoperatively and discharged alive, 2910 (24%) started on a statin before discharge. In our secondary analysis of the subset of patients not taking statins preoperatively, those initiated on a statin before discharge experienced higher survival at 1?year (94% vs 91%) and 5?years (89% vs 81%;P?< .001 overall) than those who remained off statin therapy, with the greatest absolute long-term survival difference in patients with rupture (87% vs 62%;P?< .001 overall). ConclusionsPreoperative statin therapy is associated with higher long-term survival but not perioperative mortality and morbidity in patients undergoing AAA repair, and initiating statin therapy in previously statin-naive patients is associated with markedly higher survival. All patients with AAAs without contraindications should receive statin therapy. In patients not taking a statin at the time of AAA repair, clinicians should consider initiating one before discharge.
机译:背景技术虽然术前和围手术动物疗法改善了几种种群的术后结果,但很少的数据检查其与腹主动脉瘤(AAA)修复后的生存结合。此外,没有存在关于启动他汀类药物在患者目前没有服用的患者的益处的数据。方法对2003年至2017年期间血管质量倡议的所有患者进行了基于患者的基于注册表的研究,没有记录他汀类药物不耐受。在我们的主要分析中,我们评估了术前汀类药治疗和长期死亡率,30天死亡率和医院内心肌梗死和中风之间的关联。作为次要分析,我们研究了未术前未服用他汀类药物的患者的队列,并根据它们是否在他汀类药物上排出来进行长期死亡率。为了解释治疗的非谐振分配,我们构建了倾向分数并应用了反概率加权。结果我们确定了40,452 AAA维修,其中37,950符合我们的入门标准(29,257 endocustular和8693张)。总体而言,25,997名患者(69%)术前服用他汀类药物,患者接受血管内动脉瘤修复的患者比经历开放修复的那些患者更频繁地进行(69%,比66%; P?<.001)。在倾向加权后,术前汀类药物治疗与30天死亡或医院中风或心肌梗塞无关。然而,与没有(P_X.001总体)的人相比,服用术前的患者术前经历的患者术前调整后的1年(94%vs 90%)和5年(85%vs 81%)生存,尽管亚组分析表明,这仅适用于完整或症状的动脉瘤。在11,941名患者中,没有术前和排出的他汀类药物,2910(24%)在排出前在他汀类动物中开始。在我们对术前未服用他汀类药物的患者子集的二级分析中,在排出前在他汀类药物上发起的那些在1?年(94%vs 91%)和5岁(89%与81%)上进行更高的存活率(94%vs 81%; p?<。总体而言,001总体而言,那些患有他汀类药物治疗的人,破裂患者的绝对绝对的长期存活差异(87%vs 62%;总体而言)。结论丙二醛毒素治疗与较高的长期存活相关,但在接受AAA修复的患者的围闭性死亡率和发病率相关,并在先前的他汀类幼稚患者中启动他汀类药物治疗与显着提高的存活相关。所有没有禁忌症的AAA患者都应该接受他汀类药物治疗。在AAA修复时没有服用他汀类药物的患者,临床医生应考虑在出院前启动一个。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号